Literature DB >> 23222502

Thrombosis as an intravascular effector of innate immunity.

Bernd Engelmann1, Steffen Massberg.   

Abstract

Thrombosis is the most frequent cause of mortality worldwide and is closely linked to haemostasis, which is the biological mechanism that stops bleeding after the injury of blood vessels. Indeed, both processes share the core pathways of blood coagulation and platelet activation. Here, we summarize recent work suggesting that thrombosis under certain circumstances has a major physiological role in immune defence, and we introduce the term immunothrombosis to describe this process. Immunothrombosis designates an innate immune response induced by the formation of thrombi inside blood vessels, in particular in microvessels. Immunothrombosis is supported by immune cells and by specific thrombosis-related molecules and generates an intravascular scaffold that facilitates the recognition, containment and destruction of pathogens, thereby protecting host integrity without inducing major collateral damage to the host. However, if uncontrolled, immunothrombosis is a major biological process fostering the pathologies associated with thrombosis.

Entities:  

Mesh:

Year:  2012        PMID: 23222502     DOI: 10.1038/nri3345

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  103 in total

Review 1.  Platelets and the innate immune system: mechanisms of bacterial-induced platelet activation.

Authors:  D Cox; S W Kerrigan; S P Watson
Journal:  J Thromb Haemost       Date:  2011-06       Impact factor: 5.824

2.  Thrombosis and embolism after injury.

Authors:  S Sevitt
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1970

3.  Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis.

Authors:  Robert Silasi-Mansat; Hua Zhu; Narcis I Popescu; Glenn Peer; Georgia Sfyroera; Paola Magotti; Lacramioara Ivanciu; Cristina Lupu; Tom E Mollnes; Fletcher B Taylor; Gary Kinasewitz; John D Lambris; Florea Lupu
Journal:  Blood       Date:  2010-05-13       Impact factor: 22.113

4.  Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis.

Authors:  A Angelillo-Scherrer; P de Frutos; C Aparicio; E Melis; P Savi; F Lupu; J Arnout; M Dewerchin; M Hoylaerts; J Herbert; D Collen; B Dahlbäck; P Carmeliet
Journal:  Nat Med       Date:  2001-02       Impact factor: 53.440

5.  Plasminogen is a critical host pathogenicity factor for group A streptococcal infection.

Authors:  Hongmin Sun; Ulrika Ringdahl; Jonathon W Homeister; William P Fay; N Cary Engleberg; Angela Y Yang; Laura S Rozek; Xixi Wang; Ulf Sjöbring; David Ginsburg
Journal:  Science       Date:  2004-08-27       Impact factor: 47.728

6.  Lipopolysaccharide from enterohemorrhagic Escherichia coli binds to platelets through TLR4 and CD62 and is detected on circulating platelets in patients with hemolytic uremic syndrome.

Authors:  Anne-lie Ståhl; Majlis Svensson; Matthias Mörgelin; Catharina Svanborg; Phillip I Tarr; Jody C Mooney; Sandra L Watkins; Roger Johnson; Diana Karpman
Journal:  Blood       Date:  2006-03-02       Impact factor: 22.113

Review 7.  Fibrin and fibrinolysis in infection and host defense.

Authors:  J L Degen; T H Bugge; J D Goguen
Journal:  J Thromb Haemost       Date:  2007-07       Impact factor: 5.824

8.  Restoration of NET formation by gene therapy in CGD controls aspergillosis.

Authors:  Matteo Bianchi; Abdul Hakkim; Volker Brinkmann; Ulrich Siler; Reinhard A Seger; Arturo Zychlinsky; Janine Reichenbach
Journal:  Blood       Date:  2009-06-18       Impact factor: 22.113

9.  Defective thrombus formation in mice lacking coagulation factor XII.

Authors:  Thomas Renné; Miroslava Pozgajová; Sabine Grüner; Kai Schuh; Hans-Ulrich Pauer; Peter Burfeind; David Gailani; Bernhard Nieswandt
Journal:  J Exp Med       Date:  2005-07-11       Impact factor: 14.307

10.  Direct evidence for Hageman factor (factor XII) activation by bacterial lipopolysaccharides (endotoxins).

Authors:  D C Morrison; C G Cochrane
Journal:  J Exp Med       Date:  1974-09-01       Impact factor: 14.307

View more
  485 in total

Review 1.  Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation: a perspective from Japan.

Authors:  Toshiaki Iba; Jecko Thachil
Journal:  Int J Hematol       Date:  2015-11-20       Impact factor: 2.490

Review 2.  Necroinflammation in Kidney Disease.

Authors:  Shrikant R Mulay; Andreas Linkermann; Hans-Joachim Anders
Journal:  J Am Soc Nephrol       Date:  2015-09-02       Impact factor: 10.121

3.  Relevant role of von Willebrand factor in neutrophil recruitment in a mouse sepsis model involving cecal ligation and puncture.

Authors:  Shogo Kasuda; Hideto Matsui; Shiro Ono; Yasunori Matsunari; Kenji Nishio; Midori Shima; Katsuhiko Hatake; Mitsuhiko Sugimoto
Journal:  Haematologica       Date:  2015-10-22       Impact factor: 9.941

4.  Selective factor VIII activation by the tissue factor-factor VIIa-factor Xa complex.

Authors:  Yuichi Kamikubo; G Loredana Mendolicchio; Antonella Zampolli; Patrizia Marchese; Andrea S Rothmeier; Jennifer Nagrampa Orje; Andrew J Gale; Sriram Krishnaswamy; András Gruber; Henrik Østergaard; Lars C Petersen; Wolfram Ruf; Zaverio M Ruggeri
Journal:  Blood       Date:  2017-07-20       Impact factor: 22.113

5.  Structural basis of the leukocyte integrin Mac-1 I-domain interactions with the platelet glycoprotein Ib.

Authors:  Juliet Morgan; Muhammad Saleem; Ruiqi Ng; Caroline Armstrong; Szu S Wong; Simon G Caulton; Alice Fickling; Huw E L Williams; Adam D Munday; José A López; Mark S Searle; Jonas Emsley
Journal:  Blood Adv       Date:  2019-05-14

6.  Trauma hemostasis and oxygenation research position paper on remote damage control resuscitation: definitions, current practice, and knowledge gaps.

Authors:  Donald H Jenkins; Joseph F Rappold; John F Badloe; Olle Berséus; Lorne Blackbourne; Karim H Brohi; Frank K Butler; Andrew P Cap; Mitchell Jay Cohen; Ross Davenport; Marc DePasquale; Heidi Doughty; Elon Glassberg; Tor Hervig; Timothy J Hooper; Rosemary Kozar; Marc Maegele; Ernest E Moore; Alan Murdock; Paul M Ness; Shibani Pati; Todd Rasmussen; Anne Sailliol; Martin A Schreiber; Geir Arne Sunde; Leo M G van de Watering; Kevin R Ward; Richard B Weiskopf; Nathan J White; Geir Strandenes; Philip C Spinella
Journal:  Shock       Date:  2014-05       Impact factor: 3.454

Review 7.  The immunopathology of sepsis and potential therapeutic targets.

Authors:  Tom van der Poll; Frank L van de Veerdonk; Brendon P Scicluna; Mihai G Netea
Journal:  Nat Rev Immunol       Date:  2017-04-24       Impact factor: 53.106

Review 8.  Systems biology of platelet-vessel wall interactions.

Authors:  Yolande Chen; Seth Joel Corey; Oleg V Kim; Mark S Alber
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

9.  Healthcare burden of venous thromboembolism in childhood chronic renal diseases.

Authors:  Bryce A Kerlin; William E Smoyer; James Tsai; Sheree L Boulet
Journal:  Pediatr Nephrol       Date:  2014-12-07       Impact factor: 3.714

10.  Disulfide HMGB1 derived from platelets coordinates venous thrombosis in mice.

Authors:  Konstantin Stark; Vanessa Philippi; Sven Stockhausen; Johanna Busse; Antonella Antonelli; Meike Miller; Irene Schubert; Parandis Hoseinpour; Sue Chandraratne; Marie-Luise von Brühl; Florian Gaertner; Michael Lorenz; Alessandra Agresti; Raffaele Coletti; Daniel J Antoine; Ralf Heermann; Kirsten Jung; Sven Reese; Iina Laitinen; Markus Schwaiger; Axel Walch; Markus Sperandio; Peter P Nawroth; Christoph Reinhardt; Sven Jäckel; Marco E Bianchi; Steffen Massberg
Journal:  Blood       Date:  2016-08-29       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.